[SCHEDULE 13G/A] Sarepta Therapeutics,, Inc. SEC Filing

Rhea-AI Filing Summary

Sarepta Therapeutics received a Schedule 13G/A from Capital International Investors disclosing a passive, beneficial holding of 524,146 common shares, equal to 0.5% of the 98,277,032 shares reported outstanding. The filing identifies Capital International Investors as a division of Capital Research and Management Company and related investment management entities and states that those entities are collectively deemed the beneficial owner of the position.

The report shows detailed control metrics: sole voting power for 523,807 shares, sole dispositive power for 524,146 shares and no shared voting or dispositive power. The filing also certifies the shares are held in the ordinary course of business and not to change or influence control of the issuer.

Positive

• Provides clear, specific disclosure of beneficial ownership: 524,146 shares representing 0.5% of the reported outstanding common stock.
• Details control metrics with sole voting power for 523,807 shares and sole dispositive power for 524,146 shares, improving transparency.

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine passive disclosure — CII holds 524,146 SRPT shares (0.5%), a non‑controlling stake with clear voting/dispositive breakdowns.

The position represents a small stake relative to the reported float and falls well below 5%, so it is unlikely to affect company control or market dynamics on its own. The filing provides useful granularity: sole voting power over 523,807 shares and sole dispositive power over 524,146 shares. For investors, the filing mainly confirms ownership and governance posture rather than signaling strategic change.

Corporate Governance Expert

TL;DR: Governance disclosure is complete and consistent with a passive investor profile; no group affiliations or control intent are indicated.

The Schedule 13G/A classifies the filer as an investment adviser division and explicitly states the securities are held in the ordinary course of business, which aligns with passive investor treatment. The absence of shared voting/dispositive power and the certification against influencing control reduce regulatory and governance concerns. The filing does not identify any subgroup arrangements or intentions to form a group to impact issuer control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Sarepta Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

803607100

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 803607100

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 523,807.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 524,146.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

524,146.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sarepta Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA 02142
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 803607100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 524,146 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 524,146 shares or 0.5% of the 98,277,032 shares believed to be outstanding.
(b)	Percent of class: 0.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 523,807
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 524,146
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	08/12/2025

FAQ

How many Sarepta (SRPT) shares does Capital International Investors report owning?

The filing reports beneficial ownership of 524,146 shares of Sarepta common stock.

What percentage of SRPT does the 524,146 share position represent?

The position represents 0.5% of the 98,277,032 shares the filing cites as outstanding.

Does Capital International Investors have voting power over these SRPT shares?

Yes. The filing reports sole voting power for 523,807 shares and 0 shared voting power.

Does the filer have the power to dispose of the reported SRPT shares?

Yes. The filer reports sole dispositive power for 524,146 shares and 0 shared dispositive power.

Is this ownership reported as being held to influence control of Sarepta?

No. The certification states the securities are held in the ordinary course of business and not to change or influence control of the issuer.